Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating income | -$10.0M | -$15.6M | -$12.3M | -$5.45M | -$12.2M | -$28.0M |
| Net income | -$10.3M | -$16.0M | -$12.2M | -$5.30M | -$12.3M | -$34.3M |
| EPS (diluted) | -$2.10 | -$1.92 | -$1.11 | -$7.05 | -$12.52 | -$7.13 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$3.90M | -$15.7M | -$11.5M | -$4.87M | -$8.79M | -$15.6M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.8M | $14.0M | $7.03M | $3.32M | $14.8M | $6.52M |
| Total assets | $31.5M | $15.8M | $8.37M | $4.17M | $94.3M | $90.2M |
| Total liabilities | $1.53M | $1.28M | $1.04M | $359K | $30.0M | $15.3M |
| Shareholders' equity | $29.9M | $14.5M | $7.33M | $3.81M | -$10.1M | $74.9M |
| Retained earnings | -$28.0M | -$43.9M | -$56.2M | -$61.5M | -$73.8M | -$108M |
| Shares (wtd avg diluted) | 4.93M | 8.33M | 11.1M | 751K | 1.03M | 4.98M |
Every figure is extracted from Dogwood Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.